Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt
Annals of African Medicine · 2023
DOI: 10.4103/aam.aam_209_21 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of African Medicine, 2023. Verfasst von Nagla Adel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Services, Children's Cancer Hospital Egypt, Cairo, Egypt. Hauptthemen laut MEDLINE: Carbapenem-Resistant Enterobacteriaceae, Bacteremia, Sepsis, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege, Kinderkrankenpflege
Abstract (Originalsprache)
Background
Carbapenem resistant Enterobacteriacae (CRE) bloodstream infection (BSI) causes complicated infections, especially in immunocompromised patients. This study aimed to assess the renal toxicity and the efficacy of therapy with colistin in a cohort of pediatric cancer patients with BSIs due to CRE and sensitivity to colistin. Patients and Methods: This was an observational, prospective cohort study from May 2017 to October 2017 in Children's Cancer Hospital Egypt 57,357. All patients who had blood stream infections due to CRE receiving intravenous colistin were prospectively enrolled. We used a standardized case form to record patient characteristics, including age, sex, weight, underlying comorbidities, type of infection, causative organism, and antibiotic susceptibility testing. Daily doses, duration of colistin therapy, and co-administered antibiotics (aminoglycosides, vancomycin) were collected. Furthermore, clinical and microbiological responses to treatment were reported. The dosing schedule was based on a loading dose of 5 MU and a 5-MU twice-daily divided maintenance dose, titrated on renal function. Clinical cure, bacteriological clearance, and daily serum creatinine were recorded.
Results
One hundred and forty-one Blood Stream infectious episodes mainly due to Klebsiella Species (pneumoniae and Oxytoca) (27%) and Escherichia coli (68%) were analyzed. All strains were susceptible to colistin with Minimum inhibitory concentration (MICs) of 0.19–1.5 mg/L. Patients were predominantly females (69%), with a mean age of 7 years. It was used as a combination therapy with carbapenems (69.2%) or aminoglycosides (80%). The median duration of treatment was 9 days (Range 1–50 days). Clinical and microbiological cure was observed in 110 cases (80%). Acute kidney injury developed during five treatment courses (4%) in which colistin was used in combination with amikacin. No renal replacement therapy was required and subsided within 7 days from colistin discontinuation.
Conclusions
Our study showed that colistin had a high efficacy without significant renal toxicity in severe infections due to CRE Gram-negative bacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Services, Children's Cancer Hospital Egypt, Cairo, Egypt.
- Department of Pediatric Oncology, National Cancer Institute, Cairo University, Giza; Department of Pediatric Oncology, Children's Cancer Hospital Egypt, Cairo, Egypt.
- Department of Clinical Pathology, Cairo University, Giza; Department of Microbiology, Children's Cancer Hospital Egypt, Cairo, Egypt.
- Department of Pharmacology, Toxicology and Biochemistry Faculty of Pharmacy, Future University in Egypt, Giza, Egypt.
Zitieren
APA
Adel, N., Khedr, R., Elanany, M., Zaki, H. F., Hafez, H., & El-Abhar, H. (2023). Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt. Annals of African Medicine. https://doi.org/10.4103/aam.aam_209_21
Vancouver
Adel N, Khedr R, Elanany M, Zaki HF, Hafez H, El-Abhar H. Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt. Annals of African Medicine. 2023. doi:10.4103/aam.aam_209_21
BibTeX
@article{Adel2023,
author = {Adel, Nagla and Khedr, Reham and Elanany, Mervat and Zaki, Hala F and Hafez, Hanafy and El-Abhar, Hanan},
title = {Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt},
journal = {Annals of African Medicine},
year = {2023},
doi = {10.4103/aam.aam_209_21}
}
EUVIMED